Acura Pharmaceuticals, Inc. is a pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three proprietary platform technologies, which can be used to develop multiple products. The Company's Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. The Company has also developed Impede Technology, which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. The Company's third abuse deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested.